New results soon (hopefully): A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

[Maxone73]

Not the latest, but some more insight, since results should be on their way

clinicaltrials.ucsf.edu/tri...

but they are already working on another CD46-targeted alpha therapy based on YS5, a radioimmunoconjugate.

jeccr.biomedcentral.com/art... promising and powerful (but still in-vivo only)

ah if we had the immune system of rats...we would not even be talking about prostate cancer probably!

[PCaWarrior]

Wife always says I am part rat. Unfortunately it appears it isn't the immune system part.

[Maxone73 in reply to PCaWarrior]

yeah! and that's the part we need!

[j-o-h-n in reply to Maxone73]

Thank God you post every day......it assures me that I'm still alive........(that and my morning pee of course)....Keep up the good work.

p.s. I bet you're on Tik Tok....

Good Luck, Good Health and Good Humor.

j-o-h-n Monday 11/13/2023 1:56 PM EST

[Maxone73 in reply to j-o-h-n]

Likewise John! 😜

[Ian99]

Thanks for posting. Hope to see results soon as estimated completion was Oct 31.

[Darryl Partner]

The clinical trial NCT03575819, sponsored by Fortis Therapeutics, Inc., focuses on evaluating the safety and efficacy of a drug called FOR46 for patients with metastatic castration-resistant prostate cancer (mCRPC). This Phase 1 interventional clinical trial, which began on February 4, 2019, involves administering FOR46 intravenously every 21 days. The trial comprises two parts: a dose escalation to identify the maximum tolerated dose (MTD) of FOR46, and a dose expansion to further assess the drug's safety, tolerability, and antitumor activity at the established MTD. As of the last update on May 3, 2023, the trial was active but not recruiting new participants.